MindBio Therapeutics Issues Restricted Stock Units and Converts Payables to Shares

October 8, 2025 — Leads & Copy — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), a biopharmaceutical company focused on mental health treatments, has issued 6,000,000 Restricted Stock Units (RSUs) to independent directors in lieu of cash compensation, with CEO and Executive Director Justin Hanka receiving 14,000,000 RSUs. Additionally, 45,000,000 RSUs were issued to staff and contractors. The RSUs vest upon a defined "Vesting Event," with one share issued for each vested RSU.

Two non-related party suppliers have agreed to convert CAD$161,000 of payables into 17,888,889 shares, priced at $0.009 per share, pending board and Canadian Securities Exchange approval.

Justin Hanka, CEO of MindBio Therapeutics, emphasized the importance of securing talented individuals, aligning their interests with the company's success as it progresses into the next stage of clinical trials.

MindBio is completing Phase 2B clinical trials and aims to redefine mental health treatment by scaling regulated take-home use of psychedelic medicines.

Justin Hanka, Chief Executive Officer 61 433140886 justin@mindbiotherapeutics.com

Media Inquiries Kristina Spionjak pr@hlthcommunications.com

Source: MindBio Therapeutics Corp.